Healthcare News

Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is a rare autoimmune disease of the central nervous...

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with...

Corline Biomedical AB (”Corline”) publicerar idag sin årsredovisning för bokföringsåret 2025, vilken tillgängliggörs via bolagets hemsida www.corline.se. För mer information om Corline, vänligen...

WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the...

Xeltis announces new 12 month clinical data from the aXess multi-center EU pivotal trial

Drew Woodmansee Board Appointment strengthens Trethera with deep patent expertise and capital formation experience, supporting its next phase of growth.

Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients...

ITM today announced that it will provide quality of life data from its Phase 3 COMPETE trial in a poster presentation at ASCO 2026.

As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG U.S....

SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1...